a Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management , SVKM's NMIMS , Mumbai , India.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):696-705. doi: 10.1080/21691401.2019.1576709.
In recent years, the application of vaccines shows limitations, including the high number of vaccine administrations and the fear of safety and effectiveness. In this regard, advanced vaccine products have been developed, like the combined vaccines, or are under development, such as nucleic acid vaccines (DNA and RNA), polymer-based vaccines, etc. Moreover, the possible use of traditional, like aluminium hydroxide and aluminium phosphate, or innovative adjuvants, like monophosphoryl lipid A, polysaccharides and nanoparticulate system, may further increase vaccine effectiveness. This review article focuses on the combined vaccines, which, especially when they are associated with adjuvants, reduce the dosing frequency, and prolong the duration of action, thus providing better vaccine coverage. Marketed preparations, like Typhim Vi, Peda typh and Boostrix showed better vaccine coverage for diseases like typhoid, tetanus, diphtheria and acellular pertussis. The future aspect for the development of combined vaccines will protect not only against infectious diseases but likely even against various infectious conditions, like pneumonia, meningococcal infection and respiratory syncytial virus infection.
近年来,疫苗的应用显示出了一些局限性,包括接种疫苗的次数较多,以及对安全性和有效性的担忧。在这方面,已经开发出了一些先进的疫苗产品,如联合疫苗,或者正在开发中,如核酸疫苗(DNA 和 RNA)、基于聚合物的疫苗等。此外,传统的佐剂(如氢氧化铝和磷酸铝)或创新的佐剂(如单磷酰脂质 A、多糖和纳米颗粒系统)的可能应用可能进一步提高疫苗的有效性。本文综述了联合疫苗,特别是当它们与佐剂联合使用时,可以减少接种次数,延长作用时间,从而提供更好的疫苗覆盖率。已经上市的制剂,如 Typhim Vi、Peda typh 和 Boostrix,在预防伤寒、破伤风、白喉和无细胞百日咳等疾病方面显示出了更好的疫苗覆盖率。未来联合疫苗的发展方向不仅将针对传染病,而且可能还将针对各种传染病,如肺炎、脑膜炎球菌感染和呼吸道合胞病毒感染。